

## **Sarborg Expands AI Agentic Signature Platform Beyond Pharmaceuticals into Bacteria and Agrochemicals**

WILMINGTON, De -- February 24, 2026 -- Sarborg Limited (“**Sarborg**” or the “**Company**”), today announced the expansion of its proprietary AI Signature Agent platform into additional high-impact sectors, including bacteria and agrochemicals, following the successful deployment of its Pharmaceutical Signature Agent.

Sarborg is built on the principle that biological, chemical and industrial signatures can function as a universal data language to identify, interpret and generate high-value opportunities across multiple sectors. By analysing, matching and learning from large-scale signature datasets, Sarborg’s agents create a continuously evolving network of intelligence-driven insights that inform scientific and commercial decision-making.

Pharmaceuticals represented Sarborg’s initial proof of concept. Through its proprietary, patent-pending Signature Agent and its curated database of over 1,600 disease signatures (the “**Sarborg 1,600**”), the Company has demonstrated the ability to rapidly screen drug signatures, generating ranked scientific and commercial outputs in minutes, which is a stark contrast to traditional drug discovery and preclinical research, which commonly spans three to six years to identify a promising preclinical candidate<sup>1</sup>.

Importantly, pharmaceuticals are not the platform’s limitation but rather its starting point. Sarborg is fundamentally a signature-based intelligence platform, and the same agent architecture applies wherever robust, structured signatures exist.

The Company has now curated approximately 4,500 agrochemical signatures and approximately 1,600 bacterial signatures, positioning Sarborg for structured expansion into these domains. These datasets enable the deployment of the Signature Agent across agricultural and microbial applications, with the objective of identifying commercially viable and scientifically differentiated product opportunities.

“We have always viewed pharmaceuticals as our initial validation case rather than our boundary,” said Mark Taylor, Director of Sarborg. “Our Signature Agent architecture is sector-agnostic wherever meaningful signatures exist. The expansion into bacteria and agrochemicals reflects the scalability of our platform and the strength of the datasets we have curated.”

Sarborg will continue to build and expand its signature libraries across additional sectors, reinforcing its position as a cross-industry signature intelligence platform.

### **Recent Strategic Investment**

The Company recently entered into a strategic transaction with CDT Equity Inc. (“**CDT**”), pursuant to which CDT acquired a 20% equity stake in Sarborg for total consideration of \$115,000,000, implying an equity valuation of \$575,000,000.

---

<sup>1</sup> <https://intuitionlabs.ai/articles/drug-development-timeline-explained>

The consideration is to be satisfied through the issuance of 598,005 new shares of common stock in CDT and 109,978,918 pre-funded warrants, subject to shareholder approval, together with a further deferred consideration of \$8,000,000 payable upon completion of future fundraising activities.

### **About Sarborg Limited**

Sarborg is an agentic AI signature intelligence business, built on the principle that signatures can function as a universal data language to identify, interpret, and generate high-value opportunities across multiple sectors. By analysing, matching, and learning from biological, chemical, and industrial signatures, Sarborg's agents create a continuously evolving network of intelligence-driven insights.

### **Investors & Media:**

[info@sarborg.com](mailto:info@sarborg.com)

[www.sarborg.com](http://www.sarborg.com)